Search
Plasma protein fraction (human)
go.drugbank.com/drugs/DB13968ApprovedInvestigational[L2262] The proteins in PPFh are stabilized with sodium caprylate and acetyltryptophan and it contains some electrolytes such as sodium, potassium and chloride.[L2261] … It is also stated that no more than 1% of the total protein should be gamma globulin.[L2260] PPFh is a sterile, frozen solution of solvent/detergent treated human plasma.
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalDelayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.
Abametapir
go.drugbank.com/drugs/DB11932Approved[A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. … [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838]
Pyrethrum extract
go.drugbank.com/drugs/DB11087ApprovedThe active compound is absorbed by the lice and destroys them by acting on their nervous systems but is thought to exert minimal effect on humans. … Pyrethrum extract is also used used to treat head, body, and pubic lice infections.
Categories: Compounds used in a research, industrial, or household settingDonanemab
go.drugbank.com/drugs/DB16647ApprovedInvestigationalDonanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that … [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.
Fostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant … prevents the first step in the HIV-1 viral lifecycle.
Cilostazol
go.drugbank.com/drugs/DB01166ApprovedInvestigationalCilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia … It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Categories: Compounds used in a research, industrial, or household settingEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalMutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.
Nipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigational[L64042] This reduction in autoantibodies underlies its therapeutic effect across autoantibody-driven conditions.[L64042] It is administered by intravenous infusion. … [L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis.